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Abstract
Objectives:  In this preliminary prospective study, we compared unilateral and bilateral
thyroarytenoid muscle injections of Botulinum toxin (Dysport) in 31 patients with adductor
spasmodic dysphonia, who had undergone more than 5 consecutive Dysport injections (either
unilateral or bilateral) and had completed 5 concomitant self-rated efficacy and complication scores
questionnaires related to the previous injections. We also developed a Neurophysiological Scoring
(NPS) system which has utility in the treatment administration.
Method and materials: Data were gathered prospectively on voice improvement (self-rated 6
point scale), length of response and duration of complications (breathiness, cough, dysphagia and
total voice loss). Injections were performed under electromyography (EMG) guidance. NPS scale
was used to describe the EMG response. Dose and unilateral/bilateral injections were determined
by clinical judgment based on previous response. Time intervals between injections were patient
driven.
Results: Low dose unilateral Dysport injection was associated with no significant difference in the
patient's outcome in terms of duration of action, voice score (VS) and complication rate when
compared to bilateral injections. Unilateral injections were not associated with any post treatment
total voice loss unlike the bilateral injections.
Conclusion:  Unilateral low dose Dysport injections are recommended in the treatment of
adductor spasmodic dysphonia.
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Introduction
Adductor spasmodic dysphonia (ADSD) is a focal dysto-
nia of the laryngeal musculature, causing abrupt, intermit-
tent and involuntary vocal folds spasms producing a
strained and strangled speech pattern. It is idiopathic in
nature and may reflect abnormalities in central motor
processing [1].
The cardinal signs of ADSD are effortful vocal straining
and harshness, quaver and voice arrest due to laryngos-
pasm in the midst of non-effortful phonatory periods. It is
described as "speaking whilst being strangled". Examina-
tion of the larynx may reveal true and false vocal folds
hyper-adduction with laryngeal elevation and its attend-
ant effects on speech. ADSD, a disabling disorder of voice,
is characterised by involuntary disruption of phonation
with functional, social and emotional consequences [1].
Botulinum toxin is the treatment of choice for ADSD and
has been in use since the late 1980's [2-5]. It improves the
patients' perception of dysphonia, mental health and
their social function [6]. The American Academy of
Otolaryngology-Head and Neck Surgery recognizes treat-
ment with Botulinum toxin as the primary treatment for
the ADSD (Policy statement: Botulinum Toxin; Reaf-
firmed March 1st, 1999).
Botulinum toxin inhibits the release of acetylcholine at
the neuromuscular junction, causing a chemical denerva-
tion, thus resulting in muscle weakness or even paralysis
in a reversible but long standing manner. The toxin has
seven serotypes (A-G) [7,8] of which type A is commer-
cially available and used as Botox® and Dysport® formula-
tions.
Over the past two decades, in the absence of standardized
guidelines, the dosing requirements for Botulinum toxin
therapy for unilateral and or bilateral injections has varied
significantly, both between patients and between injec-
tions in any one patient. Unilateral Botulinum toxin
doses reported to vary between 2.5 mouse units (mu) [6],
4.0-4.5 mu [9,10], 5 mu [11], 15-16 mu [10,12,13], and
30 mu [14].
Bilateral doses reported to vary between 2.0 mu [10] and
2.5 mu [6,9,11,13] for each side. Both unilateral and bilat-
eral thyroarytenoid muscle injections have been reported
to be successful. To date, published literature has been
inconclusive in comparing their effectiveness [2-5,10,14].
Commercially Botulinum toxin A is available as Botox®
and Dysport®. Botox® is manufactured in the US by Aller-
gan Pharmaceuticals (Irvine, California, USA) and Dys-
port®  is manufactured in the UK by Ipsen Products
(Maidenhead, Berkshire, UK). Botox® is available as 100
units/vial of frozen lyophilized toxin (stored at -5°C,
$281.22). The toxin is shipped from the distributor in dry
ice and is stored in a freezer at -5°C until reconstitution.
Dysport® is available as 500 units/vial (stored at 2-8°C,
$308.13). Dysport® is the formulation generally used in
the UK hospitals.
A randomised controlled trial of Botox® and Dysport® sug-
gested that Dysport® tends to have higher efficacy, longer
duration, and hence higher frequency of adverse effects
[15]. The exact conversion factor for equivalence between
the preparations is varied (site specific) and remains con-
troversial. In clinical use in the larynx it is suggested that
1 Unit of Botox® is approximately equal to 3 Units of Dys-
port® [15].
In this preliminary study, we prospectively captured data
and compared unilateral and bilateral thyroarytenoid
muscle injections of Botulinum toxin in 31 patients with
adductor spasmodic dysphonia, who had undergone
more than 5 consecutive Dysport® injections (either uni-
lateral or bilateral) and had completed 5 concomitant
self-rated efficacy and complication scores questionnaires
related to the previous injections. We also attempted to
address whether treatment should be administered unilat-
erally or bilaterally and also the dose of Dysport® that pro-
duces the optimal clinical benefit. To improve
communication between disciplines (in this case neuro-
physiology and ENT) we developed a Neurophysiological
Scoring (NPS) system which, for us, had utility in the
treatment administration. This, however, was not under
research in this article. The Dysport infiltrations were
done under EMG-guidance. This scale was used on a non-
inferential basis to assess optimum needle placement
within the muscle before administration of the injection.
Materials and methods
This prospective study was carried out in the Royal
National Throat, Ear and Nose Hospital, London, UK.
Data were collected prospectively on a specific proforma
from 1998 to 2006; 68 patients (42F/26M) with ADSD
who had more than 5 consecutive Dysport® injections
were identified. However only 31 of those patients had
either unilateral or bilateral thyroarytenoid muscle injec-
tions; the rest (37 patients) had a combination of both
unilateral and bilateral injections (cross over). All diag-
noses were made by a multi-spectral analysis (including
laryngoscopy, voice analysis and speech therapist assess-
ment) by the multidisciplinary team with due considera-
tion to differential diagnoses.
An information sheet explaining the procedure in simple
non-scientific terms was given to each of the patients.
Each patient was asked to sign a consent form prior toHead & Face Medicine 2009, 5:20 http://www.head-face-med.com/content/5/1/20
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treatment. The trial protocol was approved by the local
committee of the ethics for human research.
Inclusion criteria were patients who have had only unilat-
eral or bilateral Dysport® injections for ADSD and contin-
ued on the same regimen for at least five consecutive
treatments. Also, patients needed to be more than 18
years of age. Patients were excluded if they crossed over in
treatment regimes (received unilateral and bilateral injec-
tions), had ADSD with vocal tremor or had previous
laryngeal surgery or trauma. Pregnant women were not
included in this study.
The diagnosis was made in a joint laryngology-neurology
clinic. The patients were the major factor in influencing
the choice of the course of their treatment regime. Since
both the dosage and the side(s) of the injections were
determined by clinical judgment and patient choice based
on their previous injection clinical response and side we
again point out that this was not a randomized controlled
study. Clinical judgment mainly affected needle place-
ment and dosage. The time intervals between injections
were also patient driven since patients attended when
their subjective voice quality deteriorated. The time inter-
val between injections was determined by comparing
dates of the previous and current Dysport® injections. We
reviewed 5 injection episodes with 4 time intervals and 5
pre-injection voice and neuro-physiological scores.
Assessment was immediately before the next potential
treatment episode.
In summary: the study includes patients who received five
consecutive unilateral or bilateral injections. Once thera-
peutically stabilised outside of these five injections, no
patient crossed-over treatment regimes. These five injec-
tions were not recorded from the first ever Botulinum
toxin injection that each patient received. The initial dose
and side per patient determined based upon previous
responses and patient wishes.
Data were gathered on the response to treatment and the
side effects to the previous injection (Table 1) on a stand-
ardised proforma developed by the authors. Each patient
was asked to rate their best vocal quality following the
previous injection on a six-point scale (Table 2).
The technique
Botulinum type A in the formulation of Dysport® was used
in all patients. Sequential dilutions with saline were per-
formed until 2.5 mu were present in each 0.1 ml saline.
There was no variation in the drug concentration used. All
Dysport® injections were performed using an insulated
low profile fine bore 27-gauge mono-polar needle by or
under the direct supervision of the laryngologist. No local
anesthetic was used.
Our technique is to insert the needle through the cricothy-
roid membrane and then angle it upwards and laterally to
enter the thyroarytenoid muscle. The accuracy of the nee-
dle placement was confirmed by electromyographic
(EMG) evidence of the characteristic waveforms during
sustained phonation of a vowel sound (Figures 1 and 2).
In order to improve communication between the neuro-
physiologist and the injecting surgeon we have developed
a 10-point subjective Neurophysiological Scoring (NPS)
system to describe the amplitude and specificity of the
EMG response (Table 3), where the NPS 0 to 5 (Figure 1)
represents increase in distant motor activity and 5 to 10
(Figure 2) represents rise in the local muscle field motor
activity on EMG. The NPS was recorded for each injection;
all the NPS recording were carried out by the same team,
in order to maintain consistency and a standardized inter-
pretation of the EMG waveform.
Statistical analysis
SPSS version 14 and Graph Pad Prism 4.0 statistical soft-
ware packages were used. Student t, Chi Squared and
ANOVA tests were used where appropriate with a signifi-
cance level of p < 0.05.
We recognize a number of statistical assumptions that
were made:-
￿ A sufficient washout period occurred between each
patient consultation.
￿ There was no cumulative effect of treatment either in
local drug accumulation, motor end plate loss, needle
track scarring or fibrosis from previous haematoma
formation.
Table 1: Complications of Botulinum toxin injection
Side effects
Total voice loss
Breathy voice "whispery"
Cough
Dysphagia
Table 2: Patient self-assessment of Voice Score
0 No improvement
1 Very slight improvement
2 Slight improvement
3 Moderate improvement
4 Marked improvement
5 Extreme/near normalHead & Face Medicine 2009, 5:20 http://www.head-face-med.com/content/5/1/20
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Results
Thirty-one patients (16 females/15 males) with ADSD,
who had undergone at least 5 consecutive Dysport® injec-
tions were included in our study (Table 4); those patients
had completed 5 concomitant self-rated efficacy and com-
plication scores questionnaires (Figures 3, 4, 5, 6).
There were total of 151 injection episodes, 56 unilateral
and 95 bilateral. Eleven patients received unilateral treat-
ment and 20 bilateral treatments. No patient had their
first injection of Dysport® within our study (Table 4).
The mean Dysport® dose was 3.6 ± 0.02 units (~1.2 Botox®
units) for unilateral injection group compared to the
mean total dose of 6.6 ± 0.02 units in bilateral injection
group. The mean interval between injections for the uni-
lateral group was 136 days as compared to 122 in the
bilateral group. No patient expressed any deterioration in
their voice. All the patients in the unilateral group and
90% of the patients in the bilateral group had a voice
score of more than 2. The average voice score of 94% is
consistent with other published results reported [1-
4,14,16].
Our study revealed greater mean dysphagia duration and
a shorter breathiness with the bilateral injections (Figure
4) but the difference in duration of these complications
between unilateral and bilateral treatments were not sta-
tistically significant.
There was no significant statistical difference between uni-
lateral and bilateral groups, which both had similar rates
of complications. However, the unilateral group has a
trend to lower complication rate as would be expected.
Despite our assumptions the data has passed normality
testing with an alpha score of less than "0.05". There was
a significant difference in the mean voice score (VS)
between unilateral and bilateral groups with the unilateral
groups doing better (Student t test p < 0.05). This is also
confirmed on one way ANOVA test. Even though there is
a trend with unilateral injections having a longer duration
of action this is not statistically significant. The total voice
loss may be dose related since the dosing in bilateral
patients was double the dose in unilateral patients (6.6 vs.
3.6), which could easily account for the 9 episodes of total
voice loss in the bilateral group with none in the unilat-
eral group.
Monitor showing NPS score of 2 Figure 1
Monitor showing NPS score of 2.Head & Face Medicine 2009, 5:20 http://www.head-face-med.com/content/5/1/20
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Discussion
In this study, our patients had either unilateral or bilateral
thyroarytenoid muscle injections. As expected the 'real
life' situation is reflected by the fact that we had a crosso-
ver group who had a combination of unilateral & bilateral
injections; those patients were excluded from this study.
Exclusion was considered necessary in order to compare
pure injections groups. The patients in this group repre-
sent those who were not satisfied with their previous treat-
ment. Hence our analysis group may reflect a satisfaction
bias.
The unilateral injections compared to bilateral injections
have less discomfort, less voice loss and reduced total drug
used. However, historically, bilateral injections were used
because the unilateral injections at that time were not sat-
Monitor showing NPS score of 9 Figure 2
Monitor showing NPS score of 9.
Table 3: The neurophysiological score (NPS) and its electromyographic pattern
NPS Electromyographic pattern
0 No motor activity
1 No local motor unit activity, few distant motor units
2 No local motor unit activity, moderate distant motor units
3 No local motor unit activity, abundant distant motor units
4 Occasional local activity, abundant distal motor units
5 Few low amplitude low interference pattern local field motor unit activity. moderate distal motor units
6 Moderate low amplitude low interference pattern local field motor unit activity, few distal motor units
7 Abundant low amplitude low interference pattern local field motor unit activity, no distal motor units
8 Half amplitude half interference pattern local field motor unit activity, no distal motor units
9 Near full amplitude near full interference pattern local field motor unit activity, no distal motor units
10 Full amplitude, full interference pattern local field motor unit activity, no distal motor unitsHead & Face Medicine 2009, 5:20 http://www.head-face-med.com/content/5/1/20
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isfactory. There are disadvantages of giving any injection;
these include discomfort and scarring of the injection
tract. This may later have adverse effects on voice, which
intuitively would be worse as the numbers of injections
increases. Patients' subjective perception of treatment suc-
cess was a significant indicator of outcome in this study.
Patients' prime concern is less likely to be the instrumen-
tal measurements and more likely to be about their expe-
rience in daily life. It would have been desirable to also
have an objective quantification of vocal changes. How-
ever, within the constraint of our study this was not feasi-
ble. Patients may have under or over reported their best
voice score and complication duration due to recall bias.
Using patient diaries can partially tackle this problem
however we will then face the problem with patient com-
pliance with diary completion as it drops over time [13].
As treatment was to a large extent patient driven and it is
not feasible to blind them to treatment, patient reporting
bias can not be totally eliminated.
The efficacy/benefit and complications profile were not
significantly different. The unilateral injection involved
only a single needle puncture and as would be expected
from a single sided treatment is not associated with total
voice loss. Furthermore it should be noted that the total
volume of Dysport® is increased in bilateral injections
without a commensurate improvement in outcome. The
equivalence of bilateral and unilateral injection outcomes
may be explained in neurophysiological terms. Reduced
afferent feedback may cause a compensatory reduction in
efferent signaling to the contra-lateral larynx, however we
cannot support this rationale hence essentially the find-
ings remain unexplained. We feel that this would be the
subject of further physiological experimentation.
We used a lower equivalent dose of Botox® preparation
(Dysport®) than in many published studies but with sim-
ilar effectiveness [1-4,14,16]. It is possible that this is due
to more exact needle placement guided by the electro-
physiological waveform of the laryngeal adductors but we
must assume that this is also carried out in other centres
and the differences may simply be a statistical aberration.
Whereas some studies have shown a greater voice
improvement and duration of response with the bilateral
injections [9,11]; there have also been studies suggesting
that unilateral thyroarytenoid muscle injections are more
effective with a consistent treatment effect/side effect pro-
file than the bilateral injections [10,16]. Low dose Botuli-
num toxin, especially for the unilateral treatment in our
institution compared favorably to those reported by other
centers. This supports the cumulative dose theory propa-
gated by others [17,18] and can also decrease the likeli-
hood of developing resistance to the medication. Bilateral
Botox® doses reported generally vary between 2 & 2.5 mu
per side, whilst for the unilateral injections has been
much higher (2.5 to 30 mu per site). The amount of Dys-
port® we used was considerably below that of published
data with mean equivalent dose of 1.2 mu of Botox ® com-
Graph of voice score and laterality Figure 3
Graph of voice score and laterality. Showing a statistically significant trend for the unilateral injection group to have a bet-
ter voice score over the interval between visits.Head & Face Medicine 2009, 5:20 http://www.head-face-med.com/content/5/1/20
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pared to the range of 4-30 mu in the literature for unilat-
eral therapy.
A systematic review of 22 studies, involving Botulinum
toxin for treatment of spasmodic dysphonia showed no
significant difference in magnitude of effect between the
unilateral and bilateral injections [19]. Liu et al. and
Zwirner et al. have also shown that unilateral and bilateral
injections did not differ in their efficacy or duration in
relieving spasms [13,14]. There have also been studies
that showed no significant difference in magnitude of
effect between the unilateral and bilateral injections but
in comparison much higher doses were used for the uni-
lateral treatments [7,13,14].
The unilateral injection reduces the duration of the proce-
dure and therefore the discomfort; it also makes the use of
local anaesthesia which may interfere with EMG unneces-
sary. Knowing that the unilateral group had a high NPS,
this may empower the patient and may also have a psy-
chological effect, though this study did not specifically
look at the psychological state of the patient.
Another advantage of the unilateral injections is the
reduction in discomfort and cumulative needle injury to
thyroarytenoid muscle, which results in scarring and
fibrosis. Another plausible theory is the changes in the
central pathophysiology and or possible effect of the toxin
in the presynaptic neuron [7,20]. Unilateral low dosage
injections of Dysport® proved as successful as low dose
bilateral injections in the treatment of ADSD in this lim-
ited patient sample. However, as treatment was to a large
extent patient driven, there may be a patient reporting
bias. This, however, does not invalidate this empirical
study and is in line with other published series
[2,6,9,10,13]. No improvement (VS = 0) was seen in 8.3%
of bilateral injections compared to 2.2% in the unilateral.
Patients who did not improve were more likely to be
retreated with either higher dose or, if treated previously
with unilateral dose, bilateral dose. Although not specifi-
cally investigated, these patients are likely to be those with
more 'difficult' technical aspects to the injections. This
undoubtedly led to the slightly higher incidence of no
response in bilateral vs. unilateral injections. It also may
have caused a slight bias towards better results in unilat-
eral injections. Boutsen et al. suggested that the unilateral
injection method is associated with a better side effect
profile [21]. In the literature, bilateral injections were
found to cause more dysphagia adverse effect [11-14] and
breathiness [9,11].
Graph of episodes of complications and laterality of injections Figure 4
Graph of episodes of complications and laterality of injections. Showing that the unilateral injections group experience 
no total voice loss and are otherwise not statistically significantly different to the bilateral injection group.Head & Face Medicine 2009, 5:20 http://www.head-face-med.com/content/5/1/20
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The total mean dose Dysport® injected in our study was
3.6 mu for the unilateral and 6.6 mu (3.3 mu each side)
for the bilateral injections. Clinically this corresponds to
1.2 mu Botox® for the unilateral and the total of 2.2 mu
(1.1 mu each side) for the bilateral treatments [15,22].
Thus it appears that a relatively lower dose Botulinum
toxin A administered for the unilateral injection episodes
in our institution, compared to those reported by other
centres to produce comparable results. Our results may
support the cumulative dose theory propagated by others
[18,23,24].
Several reported series have examined the difference in
outcomes between unilateral and bilateral injections,
both in terms of voice improvement and side effects [25].
Many show a longer duration of the treatment effect with
the bilateral [9-11], compared to the unilateral injections
but some show the opposite [10]. Bielamowicz et al.
showed that the unilateral injection has more optimal
and consistent treatment effect/side effect profile [10] and
reduced the spasmodic muscle bursts in both the injected
and non-injected muscles significantly. This is related
closely to improvements in the speech symptoms [26].
In our study, we were surprised to find that so many of our
patients improved with a very low dose especially on
injections to only one side. Interestingly, many centers are
now using smaller dosages of Botulinum toxin for injec-
tions than were first used. This has been postulated to be
due to a cumulative effect of toxin over time, requiring
smaller dosage for similar efficacy [24,27].
One advantage to unilateral injections is the reduction in
cumulative needle injury to the thyroarytenoid muscle,
which results to scarring and fibrosis and possibly transac-
tion denervation. The effects of this therefore require fur-
ther investigation. In an experimental model progressive
muscle atrophy was noted [28].
Another intuitive advantage to low dosage is decreased
likelihood of development of resistance. This may just be
theoretical in importance as such low cumulative dosage
is given to the larynx. In torticollis, where much higher
dosages are required, it is a more significant issue. Greene
et al. found about 10% of patients treated for torticollis
developed resistance to Botulinum toxin type A [17].
Although to date this has not shown in cases of ADSD, it
has led others to look at other types of Botulinum Toxin
[18].
Anatomically, there is no muscle fibre communication
between the thyroarytenoid muscles on one side with the
opposite side [26]. Therefore it is unlikely that changes are
result of diffusion of Botulinum toxin to the non-injected
side. The results suggest that changes in the central patho-
physiology may play a role in changes in speech symp-
toms following treatment [26]. There is evidence that in
dystonia, Botulinum toxin transiently changes mapping
of muscle representation areas in the motor cortex, and
Graph showing the average interval between presentations and the laterality of injections Figure 5
Graph showing the average interval between presentations and the laterality of injections. The unilateral injection 
group has a trend to a longer period between visits.Head & Face Medicine 2009, 5:20 http://www.head-face-med.com/content/5/1/20
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reorganizes inhibitory and excitatory intracortical path-
ways, probably through peripheral mechanisms [29].
Moreno-Lopez et al. indicated that intracellular retrograde
axonal transport of Botulinum toxin in motor neurons
may occur, suggesting a possible effect of the toxin on the
pre-synaptic neuron. Interestingly the number of bursts in
the non-injected side was reduced to a greater degree in
patients receiving smaller dosages [26]. This correlates
with the good response to treatment to low dose unilat-
eral injection in our study.
Some studies including a review of head-to-head, rand-
omized, controlled trials of Botox® and Dysport® in pri-
mary palmar hyperhidrosis suggest that Dysport® tends to
have higher efficacy, longer duration, but higher fre-
quency of adverse effects [22,30]. Conversion factors
between the preparations are varied and remain contro-
versial.
The neurophysiological score (NPS), a 10-point subjective
scoring system, was used to describe the amplitude and
nature of the EMG response. This provided an immediate
feedback to the injecting surgeon, reducing the time taken
for each injection and hence patient discomfort. Thus we
found the use of local anaesthesia unnecessary, especially
as it may interfere with the EMG signals [31]. However,
the use of the NPS does not explain why there was no sta-
tistical difference in the mean complication duration in
the unilateral and bilateral injection groups.
The NPS can help treatment planning as a disappointing
result from one injection, in a patient who previously
responded well, may be due to poor needle placement(s)
[32]. There are certainly some patients whose anatomy
makes injection technically more challenging, and a poor
result from the last injection combined with a relatively
low neurophysiological score at that injection might lead
one to suspect technical failure [33]. Although our scoring
system is largely subjective, by working consistently with
the same neurophysiologist a level of reproducibility can
be reached which allows for meaningful longitudinal
Schematic summary showing average values for voice score (VS), neurophysiological score (NPS) and time intervals between  attendance for injection in the unilateral and bilateral injection group Figure 6
Schematic summary showing average values for voice score (VS), neurophysiological score (NPS) and time 
intervals between attendance for injection in the unilateral and bilateral injection group.Head & Face Medicine 2009, 5:20 http://www.head-face-med.com/content/5/1/20
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comparison. An inter-observer reliability test is being car-
ried out as part of another study.
Our study has assumed that there was a sufficient washout
period such that one injection methodology did not affect
the following. However this is not necessary so, as the
cumulative dose theory propagated [18,24]. Since
patients made their appointment for repeat treatments
when their subjective quality of voice deteriorated, we
assumed that the time intervals between the injection epi-
sodes were the effective duration of the therapy. However
patients may have prolonged their injection intervals due
to personal circumstances.
The use of Dysport® preparation of Botulinum toxin A in
our study may have been a confounding factor in obtain-
ing acceptable voice scores with lower clinically equiva-
lent dose compared to Botox® [22,23,34]. Several studies
have shown a greater efficacy for Dysport® injections than
Botox® injections however with increased complication
duration. In this application, this may have been a con-
founding factor and more research into pharmaco-biol-
ogy of different Botulinum toxin A preparations is
warranted. Furthermore, the type of injection (unilateral
vs. bilateral), dosing, and toxin type (Dysport vs. Botox)
are not the only variables that may influence outcomes
after injection. Volumes of reconstitution as well as con-
centration are also factors that may influence outcome as
well and adds to the difficulty in comparing different
research studies.
Other critiques of this study include the effect of the learn-
ing curve on the technique which may skew towards uni-
lateral injections over the study period. The subjective
nature of the decision of unilateral vs. bilateral was heav-
ily influenced by patient choice. This, however, does
reflect the current vogue of patient centered care and deci-
sion making and has been similarly reflected by Liu et al
[13]. Further negative skew could be attributed by self
selection of patients who required further treatment and
hence attendance for injection therapy. Further, it may be
inferred that patients may have preferred one injection
episode to two; however, this inference is not without
clinical significance. The use of established objective
voice-related quality of life questionnaires (i.e. V-RQOL,
VHI...etc.) would help.
Conclusion
We recommend the use of unilateral injections for the
treatment of ADSD. The advantages of unilateral injec-
tions are that there is no total voice loss so the patient can
phonate and less drug dose is used. Treatment planning
should be tailored to individuals keeping an acceptable
balance between symptom relief and side effects. Obvi-
ously, further prospective studies are warranted, perhaps
incorporating the use of voice related quality of life V-
RQOL.
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Table 4: Profile of treated cases (31 patients)
Category Unilateral group Bilateral group
Gender
Male 69
Female 51 1
Age (years)
Mean 55.65 58.52
Median 63.52 60.54
SD 15.45 16.03
Injection episodes 56 95
Mean interval between injections (days) 136.05 ± 56.2 122.68 ± 52.04
Mean voice score 4.24 3.93
Complications 26 episodes 59 episodes
Total voice loss 0 9 ± 5.73 (n = 6)
Breathy voice "whispery" 9.31 ± 7.76 (n = 16) 6.57 ± 4.88 (n = 35)
Cough 2.4 ± 0.89 (n = 5) 5.45 ± 6.23 (n = 11)
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